Reviewing OptimizeRx (NASDAQ:OPRX) and Corpay (NYSE:CPAY)

Corpay (NYSE:CPAY) and OptimizeRx (NASDAQ:OPRX) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Corpay and OptimizeRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corpay	0	3	11	1	2.87
OptimizeRx	0	3	6	0	2.67

Corpay presently has a consensus price target of $399.71, suggesting a potential upside of 8.29%. OptimizeRx has a consensus price target of $9.06, suggesting a potential upside of 61.83%. Given OptimizeRx’s higher possible upside, analysts clearly believe OptimizeRx is more favorable than Corpay.

Earnings and Valuation

This table compares Corpay and OptimizeRx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corpay	$3.97 billion	6.47	$981.89 million	$13.98	26.40
OptimizeRx	$71.52 million	1.44	-$17.57 million	($1.33)	-4.21

Corpay has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Corpay, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Corpay has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Insider & Institutional Ownership

98.8% of Corpay shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 6.1% of Corpay shares are held by company insiders. Comparatively, 6.1% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Corpay and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corpay	25.25%	41.46%	7.55%
OptimizeRx	-27.41%	-4.92%	-3.41%

Summary

Corpay beats OptimizeRx on 12 of the 14 factors compared between the two stocks.

About Corpay

Corpay, Inc. operates as a payments company that helps businesses and consumers manage vehicle-related expenses, lodging expenses, and corporate payments in the United States, Brazil, the United Kingdom, and internationally. The company offers vehicle payment solutions, which include fuel, tolls, parking, fleet maintenance, and long-haul transportation services, as well as prepaid food and transportation vouchers and cards. It also provides corporate payment solutions consisting of accounts payable automation; virtual cards, cross-border solutions; and purchasing and travel and entertainment card products, as well as lodging payments solutions for employees who travel overnight for work purposes; traveling crews and stranded passengers from airlines and cruise lines; and insurance policyholders displaced from their homes due to damage or catastrophe. In addition, the company offers gifts and payroll cards. It serves business, merchant, consumer, and payment network customers. The company was formerly known as FLEETCOR Technologies, Inc. and changed its name to Corpay, Inc. in March 2024. Corpay, Inc. was founded in 1986 and is headquartered in Atlanta, Georgia.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.